去纤维钠对肝小静脉闭塞病能有多大的疗效？

(also known as defibrotide) is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). Based on its anticoagulant, fibrinolysis-promoting, and anti-inflammatory effects, Richardson et al. first explored its application in the treatment of HVOD after HSCT. This study included 19 sHVOD patients. The recommended dose of defibrinated sodium is 5~60 mg/kg per day, intravenous infusion, and the median usage time is 15 days (2-61 days). The results showed that 42% of patients achieved complete remission (CR), and the overall survival (os) rate 100 days after transplantation reached 32%, and the patients could tolerate defibrinated sodium well. Since then, many clinical trials have confirmed the effectiveness of defibrinated sodium in the treatment of HVOD.

The effect of defibrotide was studied in the treatment of HVOD in children with a median age of 8.2 years (range, 0.2-20 years). The results showed that the complete response (CR) rate was 76%, and the overall survival (OS) rate 100 days after transplantation was 64%. Among them, the CR rate of 22 SHVOD patients was 50%, and the OS rate 100 days after transplantation was 36%.

For some patients with leukemia and lymphoma, hematopoietic stem cell transplantation (HSCT) is the only hope to cure the disease and regain health. Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide sodium (defibrinoside) can effectively improve the 100-day survival rate of patients, bringing new hope to the treatment of patients.

The above is the effect of treating hepatic veno-occlusive disease. I hope it will be helpful to you.

Recommended related hot articles: /newsDetail/71766.html